Elsevier,
Clinical Immunology (Sixth Edition)
Principles and Practice
2023, Pages 361-374
This content aligns with Goal 3: Good Health and Wellbeing by providing a current understanding of the cellular and molecular basis of mammalian antifungal immunity, which shows promise for guiding immunotherapy and vaccination strategies for at-risk patients, including those with HIV/AIDS.
Elsevier,
Health Information Exchange (Second Edition)
Navigating and Managing a Network of Health Information Systems
2023, Pages 603-619
This content aligns with Goal 3: Good Health and Wellbeing by providing examples of how low- and middle-income countries (LMIC) can adopt HIE principles in one health program to gain essential implementation experience that can inform scale-up, and adoption of similar systematic approaches in the wider national health system.
Elsevier,
Viruses: From Understanding to Investigation (Second Edition), 2023, Pages 383-400
This content aligns with Goal 3: Good Health and Wellbeing by discussing HIV cell and host tropism, functions of structural, regulatory, and auxiliary proteins and provides a general overview of pathogenesis, vaccine development, and treatments.
Clinical Immunology (Sixth Edition)
Principles and Practice
2023, Pages 972-982
This content supports the SDG Goal 3: Good health and well-being by Typical histological findings of autoimmune hepatitis showing marked lymphoplasmacellular infiltration of the portal tract with interface hepatitis. the main characteristics of AIH, PBC, and PSC, with particular interest for the clinical manifestations, pathogenesis, autoantibodies, and therapeutic options.
Elsevier,
Clinical Immunology (Sixth Edition)
Principles and Practice
2023, Pages 573-585
This content links with Goal 3: Good health and well-being and Goal 10: Reduced Inequalities by focusing on the role of eosinophils in health and disease, including novel therapeutic approaches and their contribution to our understanding of the role that eosinophils play in homeostasis and pathogenesis.
Elsevier,
Clinical Immunology (Sixth Edition)
Principles and Practice
2023, Pages 832-842
This content links with Goal 3: Good health and well-being and Goal 10: Reduced Inequalities by advancing understanding of MG pathophysiology to improve current therapies and contribute to the development of novel, MG-specific therapeutics.
Elsevier,
Viral, Parasitic, Bacterial, and Fungal Infections
Antimicrobial, Host Defense, and Therapeutic Strategies
2023, Pages 757-770
This content aligns with Goal 3: Good Health and Wellbeing by discussing the use of phytomedicines and phytotherapy as economical and safe alternatives to other treatments in infectious diseases such as HIV, malaria, dengue, hepatitis, and COVID-19.
Elsevier,
Esophageal Disease and the Role of the Microbiome
2023, Pages 91-114
This content links with Goal 3: Good health and well-being and Goal 10: Reduced Inequalities by providing information about esophageal squamous cell carcinoma (ESCC) and the upper aerodigestive microbiomes role in carcinogenesis and outcomes.
Elsevier,
Oncogenic Viruses
Volume 2: Medical Applications of Viral Oncology Research
2023, Pages 253-266
Oncovirus cancer is a group of more than 100 different diseases. It can develop almost anywhere in the body. Initiation of cancer largely due to genetic changes interferes with the normal process, leading to uncontrolled cell growth. This huge cell mass transforms into a tumor, which can be benign or cancerous and can be malignant, which can grow and spread to other parts of the body. Whereas some types of cancers are nontumorous like leukemia, cancers like lymphoma and myeloma are tumorous. Apart from genetic mutations and other environmental factors such as chemical changes and change in lifestyle, approximately 12% of human cancers occur due to viruses and they are known as oncoviruses. A huge group of people harbors at least one of these oncoviruses, but few go on to develop into cancer. The path from oncovirus infection to the onset of cancer in humans involves a complex process. The viral factors and host interaction create a favorable microenvironment for oncogenesis. At present, seven human oncoviruses are known: Epstein–Barr virus (EBV), human papillomavirus (HPV), Hepatitis B and C viruses (HBV and HCV), human T-cell lymphotropic virus-1 (HTLV-1), human herpesvirus-8 (HHV-8), and Merkel cell polyomavirus (MCPyV). As the first human oncovirus, EBV was first detected in Burkitt lymphoma cells by electron microscopy in 1964. Since then work in oncovirology has been carried out on a large scale to understand the host–virus pathogenesis. Globally, around 20% of all cancers are caused by infectious agents and 12% are caused due to the oncoviruses, and of these, approximately 80% of viral cancers occur in the developing nations. With the help of the existing biochemical techniques such as genomics and proteomics, the identification of virus and their role in the cancer pathogenesis could be investigated, but still knowledge about their microenvironment and interactions is lacking. Current computational techniques support the deep mining of information, and knowledge modeling with preexisting data helps in understanding the sequence-to-sequence mapping followed by structure elucidation, which brings more curated data into the picture. Bioinformatics, cheminformatics, and amalgamation of artificial intelligence play an important role in research in the field of oncovirology. The large datasets obtained from multiple biochemical experiments contain gigabytes of data related to the sequence, structure, and interactions of oncoviruses. Techniques such as computational genomics, computational proteomics, interactomics, sequence analysis, structure modeling, systems biology, protein modeling, and computer-aided drug design have significantly contributed to making research in this field cost-effective.
